Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Site search
Search
Menu
Subscribe
Home
Contact Us
Terms of Use
Privacy Policy
Home Delivery
Subscribe
Submission Forms
Place an Ad
Weather
News
Sports
Entertainment
Calendar
Obituaries
Classifieds
Place an ad
e-Edition
Best of 2023
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Exagen Inc. - Common Stock
(NQ:
XGN
)
5.020
UNCHANGED
Streaming Delayed Price
Updated: 1:00 PM EST, Dec 24, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Exagen Inc. - Common Stock
< Previous
1
2
3
4
5
Next >
Exagen Announces Campaign for Lupus Awareness Month
May 01, 2023
From
Exagen Inc.
Via
GlobeNewswire
Exagen to Announce First Quarter 2023 Financial Results on May 15, 2023
April 24, 2023
From
Exagen Inc.
Via
GlobeNewswire
BTIG Maintains Buy Rating for Exagen: Here's What You Need To Know
March 22, 2023
Via
Benzinga
Exagen Earnings Perspective: Return On Capital Employed
March 21, 2023
Via
Benzinga
Nike, Tencent Music Entertainment And 3 Stocks To Watch Heading Into Tuesday
March 21, 2023
With US futures trading higher this morning on Tuesday, some of the stocks that may grab investor focus today are as follows:
Via
Benzinga
Exagen Earnings Preview
March 17, 2023
Via
Benzinga
Exagen Inc. Reports Fourth Quarter and Full Year 2022 Results
March 20, 2023
Record AVISE® CTD Volume in 2022
From
Exagen Inc.
Via
GlobeNewswire
Exagen to Announce Fourth Quarter and Full Year Financial Results on March 20, 2023
March 06, 2023
From
Exagen Inc.
Via
GlobeNewswire
Exagen Inc. to Participate in Upcoming March Conferences
February 27, 2023
From
Exagen Inc.
Via
GlobeNewswire
Coya Therapeutics' Expansion Of Exclusive Worldwide Licensing Agreement With ARscience Biotherapeutics Could Have Outsized Impact On Neurodegenerative And Autoimmune Diseases Treatments
February 15, 2023
Houston, Texas-based Coya Therapeutics Inc. (NASDAQ: COYA) has just taken a giant leap in making effective proprietary treatments focused on certain neurodegenerative and autoimmune diseases available...
Via
Benzinga
Exagen Inc. to Participate in the 2023 BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference
January 30, 2023
From
Exagen Inc.
Via
GlobeNewswire
Exagen Inc. Elects Tina S. Nova, Ph.D. as Executive Chair of the Board of Directors
January 23, 2023
From
Exagen Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Monday's Pre-Market Session
November 28, 2022
Via
Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
November 25, 2022
Via
Benzinga
Why Richardson Electronics Shares Surged Over 8%; Here Are 55 Biggest Movers From Friday
November 28, 2022
Gainers AEye, Inc. (NASDAQ: LIDR) shares jumped 50% to close at $1.25 on Friday. AEye recently posted a Q3 loss of $0.11 per share.
Via
Benzinga
Why Lufax Holding Shares Are Trading Lower By Over 11%; Here Are 21 Stocks Moving Premarket
November 25, 2022
Gainers VEON Ltd. (NASDAQ: VEON) shares rose 31.1% to $0.6095 in pre-market trading after the company agreed to sell its Russian business, Vimpelcom for 130 billion roubles ($2.2 billion).
Via
Benzinga
Why Coupa Software Shares Jumped Around 29%; Here Are 72 Biggest Movers From Wednesday
November 25, 2022
Gainers Kalera Public Limited Company (NASDAQ: KAL) jumped 76.9% to close at $0.1610 on Wednesday after gaining 9% on Tuesday. Kalera recently posted a Q3 loss of $0.05 per share.
Via
Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
November 24, 2022
Via
Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
November 24, 2022
Via
Benzinga
Peering Into Exagen's Recent Short Interest
November 17, 2022
Exagen's (NASDAQ:XGN) short percent of float has fallen 34.48% since its last report. The company recently reported that it has 20 thousand shares sold short, which is 0.19% of all regular shares that...
Via
Benzinga
Why Foresight Autonomous Shares Jumped 33%; Here Are 83 Biggest Movers From Yesterday
November 17, 2022
Gainers Fast Radius, Inc. (NASDAQ: FSRD) shares surged 106.3% to close at $0.21 on Wednesday after dipping around 48% on Tuesday. Fast Radius established a timeline for a Chapter 11 sale process.
Via
Benzinga
Why Target Shares Are Trading Lower By 14%? Here Are 56 Stocks Moving In Wednesday's Mid-Day Session
November 16, 2022
Gainers Fast Radius, Inc. (NASDAQ: FSRD) shares jumped 109% to $0.2115 after dipping around 48% on Tuesday. Fast Radius established a timeline for a Chapter 11 sale process.
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
November 16, 2022
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
November 15, 2022
Via
Benzinga
Why Fast Radius Shares Plunged Around 48%; Here Are 103 Biggest Movers From Yesterday
November 16, 2022
Gainers Satixfy Communications Ltd. (NYSE: SATX) shares gained 140.7% to settle at $31.80 on Tuesday.
Via
Benzinga
Why Opiant Pharmaceuticals Shares Are Trading Higher By 115%? Here Are 67 Stocks Moving In Tuesday's Mid-Day Session
November 15, 2022
Gainers SenesTech, Inc. (NASDAQ: SNES) shares surged 91.7% to $0.2751. SenesTech reported a 1-for-20 reverse stock split.
Via
Benzinga
Pinterest To $23? Plus This Analyst Slashes PT On Neoleukin Therapeutics By More Than 90%
November 15, 2022
Rosenblatt raised the price target on Pinterest, Inc. (NYSE: PINS) from $21 to $23. Rosenblatt analyst Barton Crockett maintained a Neutral rating on the stock. Pinterest shares rose 2% to $24.91 in...
Via
Benzinga
Exagen Inc. Reports Third Quarter 2022 Results
November 14, 2022
Medicare Reimbursement Returns
From
Exagen Inc.
Via
GlobeNewswire
Exagen Inc. to Participate in Fourth Quarter Investor Conferences
November 08, 2022
From
Exagen Inc.
Via
GlobeNewswire
Earnings Scheduled For November 14, 2022
November 14, 2022
Companies Reporting Before The Bell • Opiant Pharma (NASDAQ:OPNT) is estimated to report quarterly loss at $1.49 per share on revenue of $3.68 million.
Via
Benzinga
< Previous
1
2
3
4
5
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.